The New Jersey Right to Try for Individualized Treatments Act allows patients with life-threatening or severely debilitating illnesses to request individualized investigational treatments from eligible facilities or manufacturers. These treatments are defined as drugs, biological products, or devices tailored specifically for an individual patient based on their genetic profile. To qualify for such treatments, patients must have consulted with a licensed physician, considered all FDA-approved treatment options, and provided informed written consent. The bill outlines the necessary components of the consent form, including potential outcomes and financial liabilities associated with the treatment.

Additionally, the act stipulates that eligible facilities can provide these investigational treatments without compensation and may require patients to cover manufacturing costs. Importantly, if a patient dies as a result of the treatment, their heirs will not be liable for any outstanding debts related to the treatment. The bill also protects healthcare providers from liability for adverse outcomes resulting from treatments consistent with the act, except in cases of gross negligence or willful misconduct. The act is set to take effect immediately upon passage.